131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
John M. Pagel(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David G. Maloney(Fred Hutch Cancer Center), Ted Gooley(Fred Hutch Cancer Center), Eneida R. Nemecek(Oregon Health & Science University), Katherine Ruffner(Pfizer (United States)), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Darrell R. Fisher(Richland Community College), Brenda M. Sandmaier(University of Washington), Dana C. Matthews(Fred Hutch Cancer Center), Michael B. Maris(Colorado Blood Cancer Institute), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Joseph G. Rajendran(Fred Hutch Cancer Center), H. Joachim Deeg(Fred Hutch Cancer Center)
Cited by 25
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k